Showing results (1011-1020 of 1,095) with videos related to

Sort By:
Pageof 110
The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patientsUmberto Malapelle, Francesco Passiglia, Chiara Cremolini, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Clinical and Experimental Medicine|August 6, 2024
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumabCarlo Genova, Silvia Marconi, Giovanna Chiorino, et al.
Personalized Medicine|July 8, 2022
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral centerCaterina De Luca, Francesco Pepe, Pasquale Pisapia, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
NPJ Parkinson'S Disease|August 26, 2025
Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formationAnne-Laure Mahul-Mellier, Melek Firat Altay, Niran Maharjan, et al.
Pageof 110